Review
Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD)

https://doi.org/10.1016/j.plipres.2008.08.001Get rights and content

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in Western countries and is considered the hepatic manifestation of metabolic syndrome. The hallmark of NAFLD is hepatic neutral lipid accumulation, mainly triacylglycerol, in the absence of significant ethanol consumption, viral infection or other specific etiologies. Hepatic lipid accumulation results from an imbalance between lipid availability (from circulating lipid uptake or de novo lipogenesis) and lipid disposal (via free fatty acid oxidation or triglyceride-rich lipoprotein secretion) and eventually triggers lipoperoxidative stress and hepatic injury. Each of these steps is altered in NAFLD, although to a different extent. Regulation of these pathways is complex and involves nuclear receptors, membrane transport proteins and cellular enzymes. We will review available data on different steps of hepatic lipid metabolism in NAFLD and recent advances in understanding molecular mechanisms underlying hepatic fat accumulation in these subjects.

Introduction

Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of conditions characterized histologically by hepatic steatosis in individuals without significant alcohol consumption and negative viral, congenital, and autoimmune liver disease markers. Hepatic lipid accumulation results from an imbalance between lipid availability (from circulating lipid uptake or de novo lipogenesis) and lipid disposal (via fatty acid oxidation or triglyceride-rich lipoprotein secretion) and eventually triggers lipoperoxidative stress and hepatic injury. NAFLD is now considered the hepatic manifestation of the metabolic syndrome and has insulin resistance as its hallmark [1], [2]. Previously thought to be benign, it recently became clear NAFLD encompasses a spectrum of liver disease ranging from pure, benign fatty liver to the more severe nonalcoholic steatohepatitis (NASH), a condition that may progress to cirrhosis in up to 25% of patients [3]. Furthermore, NAFLD is emerging as a risk factor for diabetes and cardiovascular disease, independently of insulin resistance, metabolic syndrome, plasma lipid levels and other traditional risk factors [4]. The specific origin of the lipids, mainly triacylglycerol (TAG), accumulating in liver has been unravelled by recent kinetic studies, and identifying the origin of the accumulated TAG and non-esterified fatty acids (NEFA) in the livers of patients with NAFLD may direct prevention and treatment of this condition.

Section snippets

Mechanisms of hepatic lipid accumulation: a kinetic perspective

From a kinetic standpoint, hepatic steatosis develops when there is an imbalance in which fatty acid uptake and de novo synthesis exceed oxidation and resecretion. The sources of fatty acids potentially contributing to fatty liver include (Fig. 1):

  • peripheral fat stored in adipose tissue that is delivered to the liver by way of the plasma NEFA pool (pathway 1). Insulin resistance is associated with dysregulation of adipose-derived fatty acid flux in the fasting state, and strong evidence exists

Hepatic non-esterified fatty acid uptake

As summarized above, circulating NEFA, either of dietary or endogenous origin, provide most of the hepatic lipid content in NAFLD. It is therefore essential to gain insight into mechanisms regulating hepatic NEFA uptake from the circulation. Ravikumar et al. observed, by using 13C magnetic resonance spectroscopy, an accelerated postprandial incorporation of dietary fatty acids (FAs) into liver TAG in patients with type 2 diabetes mellitus (4 h vs. 6 h), as well as a 50% higher FA accumulation

Hepatic de novo lipogenesis

According to recent kinetic data,, whereas DNL is only elevated postprandially in healthy subjects (20–30% VLDL–TAG), in NAFLD DNL is elevated in fasting conditions and lacks further postprandial elevation [5], [7], [79]. These observations support the concept of a paradoxically sustained elevation in hepatic lipogenic activity in NAFLD [80]. The regulation of hepatic lipogenesis involves a complex network of nuclear receptors, co-ordinately regulating enzymes involved in different steps of

Hepatic fatty acid oxidative pathways

Different hepatic FA oxidative pathways involved in the pathogenesis of NAFLD have been the subject of several recent reviews and these will be reviewed here briefly [294], [295], [296]. Most FA are metabolized through β-oxidation, which occurs mainly in mitochondria, but also in peroxisomes. A third FA metabolizing pathway is ω-oxidation by members of the cytochrome P450 4A in the endoplasmic reticulum (microsomes). The extramitochondrial FA oxidative pathways become more important in

Regulation of hepatic VLDL assembly and secretion

Recent kinetic studies have pointed out that hepatic triglyceride-rich lipoprotein secretion rate in NAFLD is actually increased in absolute terms, as in other insulin resistant conditions, but is inadequate to match the increased TAG availability in the liver: compared to insulin resistant subjects without a significant liver fat accumulation, subjects with NAFLD failed to further increase VLDL-Tg secretion rate when hepatic Tg infiltration exceeded 10% suggesting the liver of these subjects

Concluding remarks

As it can be seen from this discussion, the pathogenesis of hepatic fat accumulation is very complex and partially understood. Although the excessive flood of free fatty acids to the liver has been traditionally regarded as the key component of NAFLD, little is known The role of hepatic membrane NEFA transporters has only recently emerged, and the complex network regulating de novo lipogenesis has been only partially unravelled. Given the limited efficacy and the long term safety concerns of

Acknowledgement

This work was funded in part by the Piedmont Region Funds Comitato Interministeriale per la Programmazione Economica 2008.

References (366)

  • H. Doege et al.

    Targeted deletion of FATP5 reveals multiple functions in liver metabolism: alterations in hepatic lipid homeostasis

    Gastroenterology

    (2006)
  • B. Hubbard et al.

    Mice deleted for fatty acid transport protein 5 have defective bile acid conjugation and are protected from obesity

    Gastroenterology

    (2006)
  • D.P. Koonen et al.

    Long chain fatty acid uptake and FAT/CD36 translocation in heart and skeletal muscle

    Biochim Biophys Acta

    (2005)
  • A. Bonen et al.

    Acute regulation of fatty acid uptake involves the cellular redistribution of fatty acid traslocase

    J Biol Chem

    (2000)
  • M. Febbraio et al.

    CD36: implications in cardiovascular disease

    Int J Biochem Cell Biol

    (2007)
  • J.R. Goudriaan et al.

    CD36 deficiency increases insulin sensitivity in muscle, but induces insulin resistance in the liver in mice

    J Lipid Res

    (2003)
  • M. Febbraio et al.

    A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism

    J Biol Chem

    (1999)
  • J.J.F.P. Luiken et al.

    Increased rates of fatty acid uptake and plasmalemmal fatty acid transporters in obese Zucker rats

    J Biol Chem

    (2001)
  • M. Febbraio et al.

    A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism

    J Biol Chem

    (1999)
  • O. Gavrilova et al.

    Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass

    J Biol Chem

    (2003)
  • J. Zhou et al.

    A novel pregnane X receptor-mediated and sterol regulatory element-binding protein-independent lipogenic pathway

    J Biol Chem

    (2006)
  • L. Makowski et al.

    Fatty acid binding proteins – the evolutionary crossroads of inflammatory and metabolic responses

    J Nutr

    (2004)
  • N.R. Coe et al.

    Physiological properties and functions of intracellular fatty acid-binding proteins

    Biochim Biophys Acta

    (1998)
  • T. Helledie et al.

    Lipid-binding proteins modulate ligand-dependent trans-activation by peroxisome proliferator-activated receptors and localize to the nucleus as well as the cytoplasm

    J Lipid Res

    (2000)
  • J.C. Sacchettini et al.

    Thestructure of crystalline Escherichia coli- derived rat intestinal fatty acid-binding protein at 2.5-A resolution

    J Biol Chem

    (1988)
  • H.-L. Liou et al.

    Role of the helical domain in fatty acid transfer from adipocyte and heart fatty acid-binding proteins to membranes

    J Biol Chem

    (2002)
  • J.R. Galluzzi et al.

    Association of the A/T54 polymorphism in the intestinal fatty acid binding protein with variations in plasma lipids in the Framingham offspring study

    Atherosclerosis

    (2001)
  • E. Levy et al.

    The polymorphism at codon 54 of the FABP2 gene increases fat absorption in human intestinal explants

    J Biol Chem

    (2001)
  • S. Stan et al.

    Intestinal fatty acid binding protein and microsomal triglyceride transfer protein polymorphisms in French–Canadian youth

    J Lipid Res

    (2005)
  • E.P. Newberry et al.

    Decreased hepatic riglyceride accumulation and altered fatty acid uptake in mice with deletion of the liver fatty acid-binding protein gene

    J Biol Chem

    (2003)
  • K. Maeda et al.

    Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes

    Cell Metabolism

    (2005)
  • M. Hoekstra et al.

    Microarray analysis indicates an important role for FABP5 and putative novel FABPs on a Western-type diet

    J Lipid Res

    (2006)
  • N.J. Spann et al.

    Coordinate transcriptional repression of liver fatty acid-binding protein and microsomal triglyceride transfer protein blocks hepatic very low density lipoprotein secretion without hepatosteatosis

    J Biol Chem

    (2006)
  • J.F. Landrier et al.

    Fatty acid-binding protein (L-FABP). Gene expression is peroxisome proliferator-activated receptor-α-dependent

    J Biol Chem

    (2004)
  • C. Ameen et al.

    Activation of peroxisome proliferator-activated. Receptor-α Increases the expression and activity of microsomal triglyceride transfer protein in the liver

    J Biol Chem

    (2005)
  • F. Diraison et al.

    Differences in the regulation of adipose tissue and liver lipogenesis by carbohydrates in humans

    J Lipid Res

    (2003)
  • D. Zamora-Valdes et al.

    The endocannabinoid system in chronic liver disease

    Ann Hepatol

    (2005)
  • M.S. Brown et al.

    The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor

    Cell

    (1997)
  • X. Hua et al.

    Structure of the human gene encoding sterol regulatory element binding protein-1 (SREBF1) and localization of SREBF1 and SREBF2 to chromosomes 17p11.2 and 22q13

    Genomics

    (1995)
  • T. Yang et al.

    Crucial step in cholesterol homeostasis: sterols promote binding of SCAP to INSIG-1, a membrane protein that facilitates retention of SREBPs in ER

    Cell

    (2002)
  • J.B. Kim et al.

    Nutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1/SREBP1

    J Clin Invest

    (1998)
  • G. Musso et al.

    Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with adult treatment Panel III criteria in nonobese nondiabetic subjects

    Diabetes Care

    (2008)
  • G.C. Farrell et al.

    Nonalcoholic fatty liver disease: from steatosis to cirrhosis

    Hepatology

    (2006)
  • S. Chitturi et al.

    Fatty liver now, diabetes and heart attack later? The liver as a barometer of metabolic health

    J Gastroen Hepatol

    (2007)
  • K.L. Donnelly et al.

    Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease

    J Clin Invest

    (2005)
  • B.R. Barrows et al.

    Contributions of different fatty acid sources to very low-density lipoprotein-Triacylglycerol in the fasted and fed states

    J Clin Endocrinol Metab

    (2006)
  • B. Ravikumar et al.

    Real-time assessment of postprandial fat storage in liver and skeletal muscle in health and type 2 diabetes

    Am J Physiol Endocrinol Metab

    (2005)
  • J. Heeren et al.

    Endothelial-derived lipoprotein lipase is bound to postprandial triglyceride-rich lipoproteins and mediates their hepatic clearance in vivo

    J Mol Med

    (2002)
  • M. Merkel et al.

    Lipoprotein lipase expression exclusively in liver. A mouse model for metabolism in the neonatal period and during cachexia

    J Clin Invest

    (1998)
  • W. Stremmel et al.

    A new concept of cellular uptake and intracellular trafficking of long-chain fatty acids

    Lipids

    (2001)
  • Cited by (560)

    View all citing articles on Scopus
    View full text